Veterinary Medicines

Biosuis Entero, Emulsion for injection

Authorised
  • Porcine rotavirus, serogroup A, strain OSU 6, Inactivated
  • Escherichia coli, serotype O149:K88 (fimbrial adhesin F4ac), Inactivated
  • Escherichia coli, serotype O101:K99 (fimbrial adhesins F5 and F41), Inactivated
  • Escherichia coli, serotype K85:987P (fimbrial adhesin F6), Inactivated
  • Clostridium perfringens, type C, beta toxoid
Download as PDF

Product identification

Medicine name:
Biosuis Entero, Emulsion for injection
Biosuis Entero, süsteemulsioon
Active substance:
  • Porcine rotavirus, serogroup A, strain OSU 6, Inactivated
  • Escherichia coli, serotype O149:K88 (fimbrial adhesin F4ac), Inactivated
  • Escherichia coli, serotype O101:K99 (fimbrial adhesins F5 and F41), Inactivated
  • Escherichia coli, serotype K85:987P (fimbrial adhesin F6), Inactivated
  • Clostridium perfringens, type C, beta toxoid
Target species:
  • Pig
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Porcine rotavirus, serogroup A, strain OSU 6, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Escherichia coli, serotype O149:K88 (fimbrial adhesin F4ac), Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Escherichia coli, serotype O101:K99 (fimbrial adhesins F5 and F41), Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Escherichia coli, serotype K85:987P (fimbrial adhesin F6), Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Clostridium perfringens, type C, beta toxoid
    1.00
    relative potency
    /
    1.00
    Dose
Pharmaceutical form:
  • Emulsion for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI09AL09
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Estonia
Package description:
  • Glass Vial 1 x 10.0 millilitre(s)
  • Glass Vial 1 x 50.0 millilitre(s)
  • Glass Vial 1 x 100.0 millilitre(s)
  • Plastic (HDPE) Vial 1 x 50.0 millilitre(s)
  • Plastic (HDPE) Vial 1 x 100.0 millilitre(s)
  • Plastic (HDPE) Vial 1 x 250.0 millilitre(s)
  • Glass Vial 10 x 10.0 millilitre(s)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Bioveta a.s.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • State Agency Of Medicines
Authorisation number:
  • 1152824
Date of authorisation status change:
Reference member state:
  • Czechia
Procedure number:
  • CZ/V/0184/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 8/05/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."